Stock Comparison

ABCL vs PFE

Abcellera Biologics Inc vs Pfizer Inc

The Verdict

ABCL takes this one.

Winner

ABCL

Abcellera Biologics Inc

7.2

out of 10

Solid Pick

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$1.2B

Market Cap

$146.4B

-8.0

P/E Ratio

19.5

-194.9%

Profit Margin

11.8%

-14.8%

Return on Equity

8.4%

0.1

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

7.2

DVR Score

4.0

The Deep Dive

ABCL7.2/10

AbCellera continues to hold significant 10x potential, driven by its cutting-edge AI-powered antibody discovery platform and a strategic pivot towards internal drug development. The substantial Q4 2025 revenue beat and the impending Phase 1/Phase 2 data for ABCL635 are strong positive catalysts, de-risking its pipeline and demonstrating execution. While the company still grapples with negative pro...

Full ABCL Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.